Lobeglitazone: all 30 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.25/12.5/1000mg in Healthy VolunteersCompletedNCT07304726Phase 1
• Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/10/1000mg in Healthy VolunteersCompletedNCT07304700Phase 1
• Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy VolunteersCompletedNCT07304687Phase 1
• Evaluate the Pharmacokinetics and Safety Between the Treatment of CKD-383 and Treatment of CKD-501, D745, D150, and D029CompletedNCT05897216Phase 1
• Evaluate the Pharmacokinetics and Safety Between the Administration of CKD-383 and the Co-administration of CKD-501, D744, and D150CompletedNCT05816759Phase 1
• A Clinical Trial to Evaluate the Pharmacokinetic Profiles and Safety of CKD-383.CompletedNCT04810676Phase 1
• Clinical Trial to Investigate the Pharmacokinetics and Safety of CKD-393Status unknownNCT04706286Phase 1
• A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D759 and D150 (CKD-393)CompletedNCT04431687Phase 1
• A Clinical Trial to Investigate the Pharmacokinetic Drug Interaction and Safety of CKD-501, D745 and D150CompletedNCT04334213Phase 1
• Glucose-Lowering Effects and Safety of Adding 0.25 or 0.5 mg DuvieCompletedNCT03770052Phase 4
• Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 DiabetesCompletedNCT03739125Phase 3
• The Efficacy and Safety of CKD-501 Added to D150 Plus D759 Therapy in Patients With Type 2 DiabetesStatus unknownNCT03641352Phase 3
• Efficacy and Safety of CKD-501 Added to D150 Plus D745 25mg Therapy in Patients With Type 2 DiabetesStatus unknownNCT03627182Phase 3
• Evaluate the Drug-drugs Interaction Between Lobeglitazone and EmpagliflozinStatus unknownNCT02854748Phase 1
• CKD-396 Drug-drug Interaction Study(A) (CKD-396 DDI(A) P1)CompletedNCT02824874Phase 1
• Investigate the Effect of Food on the Pharmacokinetic Characteristics of CKD-395 in Healthy Male VolunteersCompletedNCT02648854Phase 1
• A Clinical Study to Compare the Pharmacokinetic Characteristics of CKD-395 0.5/1000 mg in Healthy Male VolunteersCompletedNCT02565368Phase 1
• Triple Combination Therapy in Type 2 Diabetic Patients Who Had Inadequate Glycemic Control With Combination TherapyCompletedNCT02338921Phase 4
• Comparison of Lobeglitazone With Pioglitazone as Initial Triple Therapy for Diabetes ManagementStatus unknownNCT02315287Phase 4
• Comparative Evaluation of Pharmacokinetics After CKD-501 Between Renal Impaired and Normal Renal Function SubjectsCompletedNCT02007941Phase 1
• A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic FunctionCompletedNCT02005744Phase 1
• Drug-drug Interaction Study(Lobeglitazone, Warfarin)CompletedNCT02002611Phase 1
• Drug-drug Interaction Study(CKD-501, Amlodipine)CompletedNCT01341392Phase 1
• Drug-drug Interaction Study (CKD-501, Ketoconazole)CompletedNCT01330563Phase 1
• The Pharmacokinetic Interaction Between CKD-501 and SulfonylureaCompletedNCT01133431Phase 1
• Efficacy and Safety of CKD-501 Versus Pioglitazone When Added to MetforminCompletedNCT01106131Phase 3
• The Effect of Food on the Pharmacokinetic Characteristics of CKD-501CompletedNCT01071720Phase 1
• Evaluate the Glycemic Control of CKD-501 in Type 2 Diabetes MellitusCompletedNCT01030679Phase 2
• Drug Interaction Between CKD-501 and MetforminCompletedNCT01005160Phase 1
• An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes MellitusCompletedNCT01001611Phase 3

← Lobeglitazone overview